---
document_datetime: 2024-07-24 18:23:07
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/entecavir-accord-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: entecavir-accord-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 2.5673387
conversion_datetime: 2025-12-25 09:18:54.08599
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Entecavir Accord

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                      | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                           |
|----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------|
| IA/0013              | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size | 02/03/2023                          | n/a                                         |                                  |                                                                                                                   |
| R/0011               | Renewal of the marketing authorisation.                                                                                                                    | 22/04/2022                          | 01/07/2022                                  | SmPC, Annex II, Labelling        | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |            |            | and PL          | Entecavir Accord in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0012/G | This was an application for a group of variations. B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate                                                                                                                                                                         | 17/03/2022 | n/a        |                 |                                                                                                                                                                |
| IA/0010   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 21/12/2021 | 04/03/2022 | Annex II and PL |                                                                                                                                                                |
| IB/0009/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 14/01/2021 | 04/03/2022 | SmPC and PL     |                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| IA/0008   | B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold the originally approved batch size                                                                                                               | 28/09/2020   | n/a        |                        | compared to   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|---------------|
| IB/0007   | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                   | 08/06/2020   | n/a        |                        |               |
| IAIN/0006 | B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer                                                                      | 24/07/2019   | n/a        |                        |               |
| T/0004    | Transfer of Marketing Authorisation                                                                                                                                                                                                                          | 18/01/2019   | 25/02/2019 | SmPC, Labelling and PL |               |
| IB/0005   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 30/01/2019   |            | SmPC                   |               |
| II/0001   | B.II.d.1.e - Change in the specification parameters and/or limits of the finished product - Change outside the approved specifications limits range                                                                                                          | 18/10/2018   | n/a        |                        |               |
| IA/0003   | B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier) - Replacement or addition of a supplier                                                                                                                   | 08/10/2018   | n/a        |                        |               |

<div style=\"page-break-after: always\"></div>

| IAIN/0002   | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing   | 08/10/2018   | 25/02/2019   | Annex II and PL   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------------|